Literature DB >> 9563004

Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice.

S Yano1, H Nokihara, M Hanibuchi, P Parajuli, T Shinohara, T Kawano, S Sone.   

Abstract

Malignant pleural effusion (PE) is a frequent problem in lung cancer. In this study, we established a model of malignant PE of human adenocarcinoma cells, PC-14, in SCID mice. Intravenously injected PC-14 cells formed colonies in the lungs as early as week 4 after tumor inoculation, and produced bloody PE in all recipient SCID mice by week 8. Pretreatment of SCID mice with anti-mouse IL-2 receptor beta chain antibody (TM-beta 1) to deplete natural killer (NK) cells markedly promoted the production of bloody PE and metastases to multiple organs, such as the lungs, liver, kidneys, and lymph nodes 4 weeks after tumor inoculation. Histological studies indicated that PC-14 cells formed colonies in the lungs, and then invaded the pleura and spread to the pleural cavity. To establish cell lines with a high potential to produce PE, we harvested PE, expanded the tumor cells in vitro, and injected them into SCID mice again. By four in vivo selection cycles in this way we obtained PC-14-PM4 cells, which produce lung metastases and PE earlier than PC-14 cells. The survival of SCID mice inoculated with PC-14-PM4 cells was significantly shorter than that of mice inoculated with PC-14 cells. The expressions of adhesion molecules, such as CD44, CD49d, ICAM-1, and MHC class I, on PC-14-PM4 cells tended to increase compared with PC-14 cells. These changes of adhesion molecules seem to be one of possible mechanisms involved in higher metastatic potential of PC-14-PM4 cells. PE models with PC-14 and PC-14-PM4 cells should be useful for biological and preclinical studies on malignant PE produced by human lung cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9563004

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  13 in total

Review 1.  Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Authors:  Seiji Yano; Yuka Matsumori; Kenji Ikuta; Hirokazu Ogino; Tamir Doljinsuren; Saburo Sone
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

2.  Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model.

Authors:  Yasunori Iwasaki; Shinzo Takamori; Masahiro Mitsuoka; Masaki Kashihara; Tatsuya Nishi; Daigo Murakami; Ryoichi Matsumoto; Hiroharu Mifune; Yuji Tajiri; Yoshito Akagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-12

3.  Malignant pleural effusion: further translational research is crucial.

Authors:  Yasuhiko Nishioka
Journal:  Transl Lung Cancer Res       Date:  2012-09

4.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-06       Impact factor: 6.914

6.  LPP inhibits collective cell migration during lung cancer dissemination.

Authors:  S Kuriyama; M Yoshida; S Yano; N Aiba; T Kohno; Y Minamiya; A Goto; M Tanaka
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

7.  Squamous metaplasia induced by transfection of human papillomavirus DNA into cultured adenocarcinoma cells.

Authors:  T Kinjo; K Kamiyama; K Chinen; T Iwamasa; K Kurihara; T Hamada
Journal:  Mol Pathol       Date:  2003-04

8.  Nitric oxide-mediated tumoricidal activity of murine microglial cells.

Authors:  Emily C Brantley; Lixia Guo; Chenyu Zhang; Qingtang Lin; Kenji Yokoi; Robert R Langley; Ewa Kruzel; Marva Maya; Seung Wook Kim; Sun-Jin Kim; Dominic Fan; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

9.  Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.

Authors:  Jörg J Jacoby; Baruch Erez; Maria V Korshunova; Ryan R Williams; Kazuhisa Furutani; Osamu Takahashi; Lynn Kirkpatrick; Scott M Lippman; Garth Powis; Michael S O'Reilly; Roy S Herbst
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

10.  Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.

Authors:  Gerald W Prager; Eva-Maria Lackner; Maria-Theresa Krauth; Matthias Unseld; Marina Poettler; Sylvia Laffer; Sabine Cerny-Reiterer; Wolfgang Lamm; Gabriela V Kornek; Bernd R Binder; Christoph C Zielinski; Peter Valent
Journal:  Mol Oncol       Date:  2010-01-07       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.